Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation

摘要

Objectives: Fingolimod is a well-established, highly effective immunomodulatory treatment for patients with relapsing-remitting multiple sclerosis (RRMS). However, little is known about disease course after its discontinuation.